Prof. Sylvain Lehmann M.D., Ph.D. is professor of Biochemistry at the Medical School of Montpellier. His clinical unit at the University Hospital Center (CHU) is in charge of the biological diagnosis of neurodegenerative disorders and he recently set up a reference Neurological biobank. 

“I specialize in mass spectrometry, with a particular focus on large-scale label-free quantification (LFQ) analyses. My research primarily concerns on characterizing Tau protein, which plays a key role in neurodegenerative diseases. I am currently pursuing a PhD as part of a hospital-university research project (RHU), which combines fundamental research and clinical applications.” ORCID

“I am a mass spectrometry scientist with nearly ten years of experience. I specialise in developing advanced analytical methods for the study of RNA modifications and nucleosides. Since 2019, I have worked at Montpellier University Hospital, where I established an LC-MS/MS method for the quantification of RNA modifications. I am an expert in LC-MS/MS method development, targeted quantification, HRMS acquisition, complex data analysis, scientific consulting and training.” ORCID

“I work in the field of mass spectrometry applied to the analysis of RNA modifications, where I guarantee an efficient workflow from sample reception and laboratory processing to final data analysis. Along the way, I discovered my interest in data interpretation, which led me to pursue a Master’s degree in Bioinformatics to better analyze and interpret complex datasets.”

“As a research technician, my work focuses on analyzing RNA modifications— whether from cellular RNA or circulating free metabolites—using mass spectrometry with an MRM approach, in a variety of biological samples. I am responsible for both the experimental preparation and data analysis, carried out as part of services for external partners as well as internal research projects.”

“My research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic and translational control. To achieve our goals, we have created the S.M.A.R.T. consortium that seeks at developing state-of-the-art tools & methods for studies on RNA epigenetic, in particular for clinical applications.”

“As a dentist specializing in periodontology, I divide my time between my hospital work at Montpellier University Hospital, my university work at Montpellier University of Odontology and my research work at the PPC. I’m currently in the second year of my PhD, working on salivary biomarkers of periodontitis.” ORCID

“I am responsible for immunoassays in the laboratory. Our portfolio of technologies, including NULISA, MSD, Olink, SiMoA or Ella, allow us to unlock both ultrasensitive, large plex, and low volume protein assay from most of biological fluids and different species. We are open to all types of collaboration or services, depending on your needs. Do not hesitate to contact us!” ORCID

University lecturer in Biochemistry and Molecular Biology, Constance Delaby is specialized in clinical trials and diagnostic activities of neurodegenerative diseases since 2011. ORCID

“Hello! As a student in a CIFRE thesis, funded by Shimadzu, my thesis project aims to develop a targeted LC-MS/MS method for the detection of the main blood biomarkers of dementia and Alzheimer’s disease in particular. This method would provide an innovative diagnostic tool and an alternative to invasive CSF assays.”

“I am currently pursuing a PhD through a CIFRE partnership with Eurofins Biomnis. My research is dedicated to the development and validation of a targeted LC-MS/MS method to quantify α-synucleins in biological fluids. The goal of this work is to establish a sensitive diagnostic tool that could support the detection of neurodegenerative diseases such as Parkinson’s disease, while offering a less invasive alternative to conventional approaches.” ORCID​

“As a doctoral student co-supervised by Prof. C. Panabières (LCCRH), I am studying the characterisation of the surfaceome of circulating metastasis-initiating tumour cells (CTCs). More specifically, the mechanisms by which CTCs evade the immune system and new therapeutic targets in immuno-oncology.”